U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07561346) titled 'Clinical Outcomes and Prognostic Biomarkers Exploration Between HER2 Low and HER2 Zero eBC Patients' on March 20.
Brief Summary: Although breast cancer remains one of the most common and fatal cancer types among women worldwide, earlier diagnosis and improved therapeutic approaches have led to decreased mortality over last years. Indeed, the use of HER2-targeted drugs has improved clinical outcomes for patients with HER2 positive breast cancer, while, on the other hand, until recently, little progress has been made for HER2-negative (IHC score 0 and 1+) patients.
However, it seems that among these HER2-negative breast cancers, substa...